Over half of gynecologic cancer patients reported aromatase inhibitor side effects, and almost one-third had arthralgias • Only 5% of patients discontinued aromatase inhibitor therapy due to side effects • Patients with measurable cancer burden less frequently reported aromatase inhibitor musculoskeletal side effects • Gabapentin or SSRI use was associated with decreased musculoskeletal side effects during aromatase inhibitor therapy

No abstract

No abstract

No abstract

No abstract